|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
OLIGOMERIX Funded by the Alzheimer's Drug Discovery Foundation to Evaluate Compounds Active Against Tau Oligomers, a Novel Target for Therapeutic Development
7/7/2008 8:50:33 AM
NEW YORK, NY--(Marketwire - July 07, 2008) - OLIGOMERIX, Inc. today announced receipt of a program related investment of $100K from the Alzheimer's Drug Discovery Foundation (ADDF). The focus of the program is to select compounds using its proprietary Alzheimer's disease (AD) screening assays active against tau oligomers, and to evaluate these compounds in a tauopathy mouse model. The work will be done in collaboration with Dr. Ottavio Arancio, MD, PhD (Columbia University Medical Center) and Dr. Donald Weaver, MD, PhD (Dalhousie University), both of whom are co-principal investigators.
|
|
|
|
|
|
|
|
|
|
|